Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Glaucoma
Biotech
Bausch + Lomb gives up on glaucoma eye drop hopeful after fail
Bausch + Lomb has abandoned its next great hope in glaucoma after the eye drops flunked a phase 2 study.
James Waldron
Jul 10, 2026 7:31am
Bayer buys Perfuse in $2.4B deal for ph. 2 eye disease prospect
May 6, 2026 7:20am
Iantrek sees $42M fundraising for alternative glaucoma surgery
Aug 20, 2025 11:50am
Glaukos nets EU green lights for glaucoma surgery micro-stents
Jun 27, 2025 1:55pm
Qlaris sees double as drug reduces eye pressure in ph. 2 trials
Feb 5, 2025 9:53am
Alcon snags Belkin Vision's automated laser glaucoma therapy
Jul 3, 2024 4:25pm
